Last reviewed · How we verify
Ifosfamide for Injection
Ifosfamide is an alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death.
Ifosfamide is an alkylating agent that cross-links DNA strands, preventing cancer cell replication and inducing cell death. Used for Germ cell testicular cancer, Lymphoma, Soft tissue sarcoma.
At a glance
| Generic name | Ifosfamide for Injection |
|---|---|
| Also known as | NSC109724 |
| Sponsor | BeBetter Med Inc |
| Drug class | Alkylating agent |
| Target | DNA (non-specific cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ifosfamide is a nitrogen mustard derivative that requires hepatic activation to its active metabolite. Once activated, it forms covalent bonds between DNA strands (cross-linking), disrupting DNA replication and transcription. This leads to apoptosis in rapidly dividing cancer cells. It is cell-cycle nonspecific and has activity against a broad range of malignancies.
Approved indications
- Germ cell testicular cancer
- Lymphoma
- Soft tissue sarcoma
- Bone sarcoma
- Cervical cancer
- Ovarian cancer
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Hemorrhagic cystitis
- Nausea and vomiting
- Alopecia
- CNS toxicity (encephalopathy, confusion)
- Nephrotoxicity
- Secondary malignancy
Key clinical trials
- Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) (PHASE3)
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (PHASE2)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (PHASE1)
- A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (PHASE2)
- N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma (PHASE2)
- Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma (PHASE3)
- MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ifosfamide for Injection CI brief — competitive landscape report
- Ifosfamide for Injection updates RSS · CI watch RSS
- BeBetter Med Inc portfolio CI